JD Health, Kingmed Partner on COVID-19 Nucleic Acid Test Booking in 11 Chinese Cities
JD.com, 4/23/20
Yesterday, five days after the opening of China's first COVID-19 nucleic acid testing online reservation platform by Chinese B2C e-commerce platform operator and retail infrastructure service provider JD.com (Nasdaq: JD)'s healthcare subsidiary and Beijing KingMed Diagnostics Laboratory, JD Health announced the expansion of this booking service from Beijing to 11 cities across the country, including Shanghai, Zhengzhou, Chengdu, Hangzhou, Hefei, Kunming, Nanjing, Qingdao, Jinan, and Haikou. Online reservation services will gradually be rolled out to 50 cities nationwide.
Through online booking, the process of COVID-19 nucleic acid testing is made convenient and simple. Users need to search for nucleic acid testing on the JD app, place an order on the designated page and select a testing place and appointment time. The test report is available through the KingMed WeChat official account within 24 hours after sampling is completed, which in addition to being convenient and timely, also helps reduce the risk of cross-infection by making multiple trips to the testing site.
This service has attracted wide attention. Data shows that four days since its release, the reservation service page has had more than 3 mln views. Among the regional distribution of users of the service, Beijing's 16% accounts for the highest proportion, followed by Shanghai, Guangzhou, Shenzhen and other cities with the most concentrated demand for business travel.
In order to enable users in more areas in China to enjoy safe and convenient nucleic acid testing services, and to facilitate residents' travel, return to work, and return to school, JD Health will also work with more partners to provide nucleic acid testing online booking service in more cities across the country. In addition, JD Health also provides group appointment-booking services to help enterprises, institutions, schools, government agencies and organizations to carry out this testing in a timely and effective manner, so as to ensure the orderly return to work and study.
KingMed (603882.SH) is a leader in China's third-party medical examination industry, relying on advantages such as virus detection capabilities and its logistics network to provide strong support and testing resources in the fight against the epidemic. As of April 22, KingMed has carried out screening, outpatient fever clinic, work resumption, school resumption and entry testing in 27 provinces, cities and regions, including Hubei, Guangdong, Anhui, Chongqing and Shaanxi, conducting over 2.9 mln tests.
Keywords: mobile healthcare e-commerce wireless B2C JD.com JD KingMed JD Health 603882.SH
Sending
